Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?
11:25am, Tuesday, 29'th Jul 2025
Key Points in This Article: Novo Nordisk's (NVO) operations update reported 18% sales and 29% operating profit growth for H1 2025, but one-off adjustments inflated results.
Novo Nordisk sinks on guidance cut
11:08am, Tuesday, 29'th Jul 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on Novo Nordisk's earnings, why the stock is under pressure, and much more.
Novo Nordisk Shares Plunge 21% Toward Worst Day In 40 Years—As Ozempic Sales Expected To Slow
11:05am, Tuesday, 29'th Jul 2025
Novo Nordisk will release its Q2 earnings report on Aug. 6.
Novo Nordisk Stock Eyes Worst Day Ever on Outlook Cut
10:01am, Tuesday, 29'th Jul 2025
Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's surprise cut to its full-year guidance due to a lower sales outlook fo
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
09:55am, Tuesday, 29'th Jul 2025
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm.
NVO Plunges 20% After Cutting Outlook, SOFI Rallies 10% After Earnings
09:45am, Tuesday, 29'th Jul 2025
Tuesday morning showed a tale of two companies. Novo Nordisk (NVO) sold off more than 20% after making heavy reductions to sales guidance for its Ozempic and Wegovy weight loss drugs.
Ozempic maker stock just collapsed
09:25am, Tuesday, 29'th Jul 2025
Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), behind the weight-loss drug Wegovy and diabetes medication Ozempic, tumbled on Tuesday after the company slashed its full-year 2025 guid
Novo Nordisk shares fall as it slashes 2025 outlook amid US sales drag
08:49am, Tuesday, 29'th Jul 2025
Copenhagen-listed shares of Novo Nordisk plunged more than 21% on Tuesday after the Danish pharmaceutical company issued a profit warning, citing weaker-than-expected sales growth for its flagship dru
Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEO
07:56am, Tuesday, 29'th Jul 2025
Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to revive sales and a share price hit by worries the Wegovy maker is falling be
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
07:36am, Tuesday, 29'th Jul 2025
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeed
Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic
07:32am, Tuesday, 29'th Jul 2025
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.
Novo Nordisk Stock Plummets After Ozempic Maker's Shock Cut to U.S. Outlook
07:29am, Tuesday, 29'th Jul 2025
The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and Ozempic in the U.S. market.
Novo Nordisk Cuts Guidance as Copycat Versions of Wegovy Hurt Results
07:25am, Tuesday, 29'th Jul 2025
The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S. regulators ordering an end to the practice.
Shares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance
07:12am, Tuesday, 29'th Jul 2025
Danish pharmaceutical giant Novo Nordisk on Tuesday cuts its full-year sales and profit guidance.
Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook
07:07am, Tuesday, 29'th Jul 2025
Obesity drugmaker Novo Nordisk warned on Tuesday that full-year sales and operating proft would grow less than previously expected, marking its second forecast cut of 2025.
